NEW YORK (GenomeWeb News) – PerkinElmer's chief executive is denying a report that the company is seeking a buyer.
In a statement e-mailed today to GenomeWeb Daily News, Robert Friel, chairman and CEO of PerkinElmer, refuted a Bloomberg News report yesterday that the company had put itself on the market following a failed bid to purchase Beckman Coulter, which is in the process of being bought by Danaher for $6.8 billion.
"Media reports containing speculation to the effect that PerkinElmer is for sale or positioning itself for sale are inaccurate," Friel said. "A sale of the company is not being discussed, and such a transaction is not in the company’s strategic plans.
"We continue to be on strategy with regard to our plans for growth, and we remain in strong financial health. PerkinElmer remains committed to growing our business and leveraging the strong foundation we've already built to achieve future growth," he continued.
Friel did not address questions about PerkinElmer's reported attempt to acquire Beckman Coulter.
On Thursday, shares of PerkinElmer traded on the New York Stock Exchange closed at $27.72, up 7 percent from Wednesday's close, driven by the report. Its stock price peaked at $28.37 during the day. About 7.4 million shares of the company's shares were traded on Thursday, more than six times the average volume for PerkinElmer's stock during the past three months.
In early Friday afternoon trading, the company's shares declined about 3 percent to $26.90.